Eli Lilly introduces Ramiven (abemaciclib) in India

Abemaciclib is a CDK4/6 inhibitor which has now been approved for HR+ HER2 - node positive high-risk Early Breast Cancer (EBC)

Eli Lilly and Company has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2(HER2) negative, node-positive Early Breast Cancer (EBC) at high risk of recurrence, a company statement said.

CDK 4/6 inhibitors are a class of medicines used to treat certain types of metastatic breast cancers. In India, over 50,000 patients are diagnosed with HR+/HER2- early breast cancer (EBC) every year. Close to 30 per cent of EBC patients with high-risk clinical or pathological features experience recurrence or metastasis despite receiving standard therapy, the statement added.

Ramiven is already approved for the treatment of certain types of HR+ HER2- advanced or metastatic breast cancer. It is a prescription drug to be used only on the advice of an oncologist and under medical supervision. It is available in tablet strengths of 150 mg, 100 mg and 50 mg for EBC, the statement concluded.


abemaciclibbreast cancer drugEli LillyRamiven
Comments (0)
Add Comment